Chen, Yi-Bin http://orcid.org/0000-0002-9554-1058
Mohty, Mohamad
Zeiser, Robert http://orcid.org/0000-0001-6565-3393
Teshima, Takanori http://orcid.org/0000-0002-0941-271X
Jamy, Omer
Maertens, Johan
Purtill, Duncan
Chen, Jingjing
Cao, Hong
Rossiter, Guillermo
Jansson, Johan
Fløisand, Yngvar http://orcid.org/0000-0001-7267-1944
Funding for this research was provided by:
Takeda
Article History
Received: 18 December 2023
Accepted: 23 April 2024
First Online: 6 June 2024
Competing interests
: Y.-B.C. has received consulting fees from Incyte, Novartis, Magenta, Daiichi, Celularity, Equillium, Vor Biopharma and Pharmacosmos. M.M. has received research funding from Sanofi and Jazz Pharmaceuticals, and honoraria from Sanofi, Jazz, Celgene, Bristol Myers Squibb, Takeda, Amgen, Astellas, Novartis, Adaptive Biotechnologies, Oncopeptides, Pfizer, GSK and Gilead Sciences. R.Z. has received consulting fees from Incyte, Novartis, MNK, Sanofi and VectivBio. T.T. has received research funding from Kyowa Kirin, Sanofi, Asahi Kasei Pharma, Chugai, Astellas, Eisai, Fuji Pharma, Nippon Shinyaku, Luca Science, Sumitomo Pharma, ONO, Shionogi, Priothera and Otsuka, and honoraria from Kyowa Kirin, Merck Sharp & Dohme, Bristol Myers Squibb, AbbVie and Celgene; participated in advisory boards for Merck Sharp & Dohme, Takeda and Novartis; and received non-financial support from Janssen, Novartis, Meiji Seika Pharma, Daiichi Sankyo, AstraZeneca and Roche Diagnostics. O.J. has participated in an advisory board for Ascentage. J.M. has participated in advisory boards for F2G, Mundipharma, Takeda, Pfizer, Gilead Sciences, Basilea and Astellas, and received speaker honoraria from F2G, Mundipharma, Takeda, Pfizer, Gilead Sciences and Basilea. D.P. has participated in advisory boards for Novartis, BMS Celgene, Jazz and Gilead, and received consulting fees from Bastion Educational. Y.F. has participated in advisory boards for Celgene, Takeda, Novartis, Otsuka and Pfizer, and received speaker honoraria from Celgene, Takeda, Novartis and Pfizer; travel grants from Celgene, Takeda, Novartis and AbbVie; and consulting fees from Dava Oncology, Arog and AbbVie. J.C., H.C., G.R. and J.J. are employees of Takeda and hold Takeda stock/stock options.